menu

CME: Clinical Debates in Multiple Myeloma: Putting Evidence Into Context

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Clinical Debates in Multiple Myeloma: Putting Evidence Into Context

Clinical Debates in Multiple Myeloma: Putting Evidence Into Context
RestartResume
This activity reviews current treatments and therapies for the management of multiple myeloma.

Available credits: 1.00

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The treatment armamentarium for multiple myeloma (MM) has expanded significantly in recent years, with 6 new agents or indications approved by the US Food & Drug Administration since 2015. Treatment options now include immunomodulatory drugs, proteasome inhibitors, a histone deacetylase inhibitor, and immunotherapies, making clinical decisions much more complex. Additionally, best practices and consensus guidelines, such as those from the National Comprehensive Cancer Network® (NCCN®) and International Myeloma Working Group (IMWG), are constantly evolving as new data are published. Approval of these new agents, revision of response criteria, and implementation of new approaches to risk assessment and monitoring residual disease are causing significant changes in the management of MM.

    This activity will review areas of current controversy and topics for which consensus is not yet established, including when to initiate treatment, determining transplant eligibility, high-risk disease, duration of maintenance therapy, sequencing newly approved drugs, and choice of treatment at relapse.

  • Faculty

    Sagar Lonial, MD, FACP
    Chair and Professor
    Department of Hematology and Medical Oncology
    Chief Medical Officer
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Apply appropriate diagnostic criteria to discern when to initiate treatment for multiple myeloma versus watch and wait
    • Assess patient- and disease-related characteristics using the frailty index and consensus guidelines to identify elderly patients with multiple myeloma who are eligible for autologous stem cell transplantation
    • Assess patients’ risk group using patient characteristics and genetic criteria and select appropriate treatment
    • Identify the appropriate type and duration of maintenance therapy for patients with multiple myeloma according to consensus guidelines
    • Evaluate current efficacy and safety data to appropriately select and sequence newly approved and emerging therapies for multiple myeloma
    • Outline considerations that inform optimal treatment decision-making for relapsed/refractory multiple myeloma
  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Sagar Lonial, MD, FACP, reported a financial interest/relationship or affiliation in the form of Consultant, Takeda Oncology, Celgene Corporation, Novartis Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., GlaxoSmithKline, Amgen, Inc.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Kristen Baileys, RN, MSN, CRNP, OCN; Stephanie Sutphin, PharmD;and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Nursing

    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provided by

  • Commercial Support

    This activity is supported by an educational grant from Takeda Oncology.

  • Disclosure of Unlabeled Use

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.